MedTrace Logo

Ocular Surface Disease and IOP Monitoring With Travoprost Without Conservatives

NCT05319470 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2023-07-05

No results posted yet for this study

Summary

Primary objective of this study is to study the efficacy of travoprost without preservatives in the treatment of glaucoma patients and to monitor the ocular surface.

Conditions

  • Glaucoma
  • Glaucoma; Drugs
  • Ocular Surface Disease

Interventions

DIAGNOSTIC_TEST

Intraocular pressure (IOP)

Measurement of intraocular pressure in both eyes of the study population using the Goldman applanation tonometer.

DIAGNOSTIC_TEST

Tear Break-up Time (TBUT)

TBUT will be calculated after instillation of a drop of fluorescein dye, by slit lamp biomicroscopy.

DIAGNOSTIC_TEST

Conjuctival Hyperemia

Conjunctival hyperemia will be assessed by slit lamp biomicroscopy using a validated grading system.

DIAGNOSTIC_TEST

Schirmer Test

Schirmer test will be performed on both eyes to asses tear production.

DIAGNOSTIC_TEST

Visual Fields and OCT RNFL

Visual field examination using a Humphrey perimeter and measurement of peripapillary retinal nerve fiber layer thickness with optical coherence tomography.

Sponsors & Collaborators

  • Democritus University of Thrace

    lead OTHER

Principal Investigators

  • Georgios Labiris, MD,PhD · Department of Ophthalmology, University Hospital of Alexandroupolis, Alexandroupolis, Greece

Eligibility

Min Age
35 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2023-04-15
Completion
2023-05-15

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05319470 on ClinicalTrials.gov